Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 577 to 580 of 580 entries
Sorted by: Best Match Show Resources per page
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.

Hepatology (Baltimore, Md.)

Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB.
PMID: 34778999
Hepatology. 2021 Nov 15; doi: 10.1002/hep.32240. Epub 2021 Nov 15.

The burden of HCC is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process-based measures and patient-reported outcomes (PROs)...

Cite
Asrani SK, Ghabril MS, Kuo A, et al. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2021;doi: 10.1002/hep.32240.
Asrani, S. K., Ghabril, M. S., Kuo, A., Merriman, R. B., Morgan, T., Parikh, N. D., Ovchinsky, N., Kanwal, F., Volk, M. L., Ho, C., Serper, M., Mehta, S., Agopian, V., Cabrera, R., Chernyak, V., El-Serag, H. B., Heimbach, J., Ioannou, G. N., Kaplan, D., Marrero, J., Mehta, N., Singal, A., Salem, R., Taddei, T., Walling, A. M., & Tapper, E. B. (2021). Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32240
Asrani, Sumeet K, et al. "Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32240
Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2021 Nov 15; doi: 10.1002/hep.32240. Epub 2021 Nov 15. PMID: 34778999.
Copy Download .nbib Format: NLM
Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.

Archiv der Pharmazie

Ragab FA, Eissa AAM, Fahim SH, Salem MA, Gamal MA, Nissan YM.
PMID: 33872414
Arch Pharm (Weinheim). 2021 Aug;354(8):e2100029. doi: 10.1002/ardp.202100029. Epub 2021 Apr 19.

New coumarin derivatives 9a-f, 10a-e, and 11a-f were synthesized and evaluated for their cytotoxic activity against a human breast cancer cell line (MCF-7). All compounds exhibited good activity in the nanomolar range, using doxorubicin and erlotinib as positive controls....

Cite
Ragab FA, Eissa AAM, Fahim SH, et al. Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents. Arch Pharm (Weinheim). 2021;354(8):e2100029doi: 10.1002/ardp.202100029.
Ragab, F. A., Eissa, A. A. M., Fahim, S. H., Salem, M. A., Gamal, M. A., & Nissan, Y. M. (2021). Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents. Archiv der Pharmazie, 354(8), e2100029. https://doi.org/10.1002/ardp.202100029
Ragab, Fatma A, et al. "Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents." Archiv der Pharmazie vol. 354,8 (2021): e2100029. doi: https://doi.org/10.1002/ardp.202100029
Ragab FA, Eissa AAM, Fahim SH, Salem MA, Gamal MA, Nissan YM. Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents. Arch Pharm (Weinheim). 2021 Aug;354(8):e2100029. doi: 10.1002/ardp.202100029. Epub 2021 Apr 19. PMID: 33872414.
Copy Download .nbib Format: NLM
Placement of Posterior Composite Restorations: A Cross-Sectional Study of Dental Practitioners in Al-Kharj, Saudi Arabia.

International journal of environmental research and public health

Awad MM, Alradan M, Alshalan N, Alqahtani A, Alhalabi F, Salem MA, Rabah A, Alrahlah A.
PMID: 34886134
Int J Environ Res Public Health. 2021 Nov 25;18(23). doi: 10.3390/ijerph182312408.

Dental practitioner-related factors can affect the quality of composite restorations. This study aimed to investigate the clinical techniques used by dental practitioners (DPs) while placing direct posterior composite restorations.METHODS: A questionnaire survey that sought information related to the placement...

Cite
Awad MM, Alradan M, Alshalan N, et al. Placement of Posterior Composite Restorations: A Cross-Sectional Study of Dental Practitioners in Al-Kharj, Saudi Arabia. Int J Environ Res Public Health. 2021;18(23)doi: 10.3390/ijerph182312408.
Awad, M. M., Alradan, M., Alshalan, N., Alqahtani, A., Alhalabi, F., Salem, M. A., Rabah, A., & Alrahlah, A. (2021). Placement of Posterior Composite Restorations: A Cross-Sectional Study of Dental Practitioners in Al-Kharj, Saudi Arabia. International journal of environmental research and public health, 18(23), . https://doi.org/10.3390/ijerph182312408
Awad, Mohamed M, et al. "Placement of Posterior Composite Restorations: A Cross-Sectional Study of Dental Practitioners in Al-Kharj, Saudi Arabia." International journal of environmental research and public health vol. 18,23 (2021). doi: https://doi.org/10.3390/ijerph182312408
Awad MM, Alradan M, Alshalan N, Alqahtani A, Alhalabi F, Salem MA, Rabah A, Alrahlah A. Placement of Posterior Composite Restorations: A Cross-Sectional Study of Dental Practitioners in Al-Kharj, Saudi Arabia. Int J Environ Res Public Health. 2021 Nov 25;18(23). doi: 10.3390/ijerph182312408. PMID: 34886134; PMCID: PMC8656557.
Copy Download .nbib Format: NLM
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.

Journal of the National Cancer Institute

Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q.
PMID: 34505880
J Natl Cancer Inst. 2022 Jan 11;114(1):60-67. doi: 10.1093/jnci/djab187.

BACKGROUND: Disease-free survival (DFS) with a 3-year median follow-up (3-year DFS) was validated as a surrogate for overall survival (OS) with a 5-year median follow-up (5-year OS) in adjuvant chemotherapy colon cancer (CC) trials. Recent data show further improvements...

Cite
Yin J, Salem ME, Dixon JG, et al. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022;114(1):60-67doi: 10.1093/jnci/djab187.
Yin, J., Salem, M. E., Dixon, J. G., Jin, Z., Cohen, R., DeGramont, A., Van Cutsem, E., Taieb, J., Alberts, S. R., Wolmark, N., Schmoll, H. J., Saltz, L. B., George, T. J., Goldberg, R. R. M., Kerr, R., Lonardi, S., Yoshino, T., Yothers, G., Grothey, A., Andre, T., & Shi, Q. (2022). Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 114(1), 60-67. https://doi.org/10.1093/jnci/djab187
Yin, Jun, et al. "Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials." Journal of the National Cancer Institute vol. 114,1 (2022): 60-67. doi: https://doi.org/10.1093/jnci/djab187
Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022 Jan 11;114(1):60-67. doi: 10.1093/jnci/djab187. PMID: 34505880; PMCID: PMC8755492.
Copy Download .nbib Format: NLM
Showing 577 to 580 of 580 entries